Valuation: Savara Inc.

Market Cap 123.51Cr 110.81Cr 102.45Cr 93Cr 173.35Cr 12TCr 175.45Cr 1.22TCr 487.91Cr 6.16TCr 463.49Cr 453.71Cr 20TCr P/E 2026 *
-8.05x
P/E 2027 * -12.5x
Enterprise Value 77Cr 69Cr 64Cr 58Cr 107.92Cr 7.32TCr 109.23Cr 762.63Cr 303.76Cr 3.83TCr 288.56Cr 282.47Cr 12TCr EV / Sales 2026 *
428x
EV / Sales 2027 * 11.4x
Free-Float
97.45%
Yield 2026 *
-
Yield 2027 * -
1 day+3.29%
1 week+7.49%
Current month-2.71%
1 month-0.99%
3 months-5.82%
Current year-16.75%
1 week 4.13
Extreme 4.13
5.05
1 month 4.13
Extreme 4.13
5.24
Current year 4.13
Extreme 4.13
6.49
1 year 3.86
Extreme 3.86
7
3 years 1.89
Extreme 1.89
7
5 years 1.02
Extreme 1.02
7
10 years 0.69
Extreme 0.69
17.19
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2020
Director of Finance/CFO 57 15/07/2026
Chief Tech/Sci/R&D Officer 56 01/12/2023
Director TitleAgeSince
Director/Board Member 59 01/02/2009
Director/Board Member 77 01/10/2010
Director/Board Member 73 01/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/26 Tax

Executive/Senior Manager

-29,323 0.0143%
15/07/26 Free

Chief Financial Officer

1,05,000 0.0512%
18/03/26 Exercice

Chief Financial Officer

8,50,254 0.4179%
Change 5-day change 1-year change 3-year change Capi.($)
+3.29%+7.49%+13.83%+36.78% 123.51Cr
+0.65%-3.56%+33.53%+60.50% 6.35TCr
+1.76%+2.10%+12.10%+81.21% 5.45TCr
-0.94%+0.77%+8.85%+100.19% 5.36TCr
+2.76%+0.87%+27.92%+57.51% 4.48TCr
+2.00%-3.39%+17.83%+100.08% 4.16TCr
+1.34%-2.86%+224.43%+928.45% 3.99TCr
+0.64%-3.85%+11.71%+45.57% 3.25TCr
+29.06%+48.65%+106.84%+92.73% 2.67TCr
+3.72%-7.45%+24.25%-2.99% 2.34TCr
Average +4.41%-0.17%+48.13%+150.00% 3.82TCr
Weighted average by Cap. +3.21%-0.28%+47.24%+160.79%

Financials

2026 *2027 *
Net sales 17.95L 16.11L 14.89L 13.49L 25.19L 17Cr 25.5L 1.78Cr 70.91L 8.95Cr 67.36L 65.94L 28Cr 7.96Cr 7.15Cr 6.61Cr 5.98Cr 11Cr 758.56Cr 11Cr 79Cr 31Cr 396.94Cr 30Cr 29Cr 1.26TCr
Net income -15Cr -14Cr -13Cr -11Cr -21Cr -1.44TCr -21Cr -149.61Cr -60Cr -751.8Cr -57Cr -55Cr -2.39TCr -9.41Cr -8.44Cr -7.81Cr -7.07Cr -13Cr -896.34Cr -13Cr -93Cr -37Cr -469.04Cr -35Cr -35Cr -1.49TCr
Net Debt -47Cr -42Cr -39Cr -35Cr -65Cr -4.44TCr -66Cr -462.33Cr -184.15Cr -2.32TCr -174.93Cr -171.24Cr -7.38TCr -33Cr -29Cr -27Cr -25Cr -46Cr -3.13TCr -47Cr -325.81Cr -129.77Cr -1.64TCr -123.28Cr -120.67Cr -5.2TCr
Projected Income Statement - Annual - Savara Inc.
Logo Savara Inc.
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
70
Date Price Change Volume
29/26/29 $5.020 +3.29% 17,85,855
27/26/27 $4.860 +7.52% 35,91,282
26/26/26 $4.520 +7.11% 34,49,003
23/26/23 $4.220 -7.05% 28,28,603
22/26/22 $4.540 -2.78% 27,10,107
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Savara Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.860USD
Average target price
11.06USD
Spread / Average Target
+127.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Savara Inc.
  1. Stock Market
  2. Stocks
  3. SVRA Stock